ERBB2 and posterior cortical atrophy: Three CDK4/6 inhibitors—abemaciclib, palbociclib, and ribociclib—have been found safe and effective in hormone receptor-positive HER2-negative breast cancer and are now undergoing clinical trials for various stages of PCa reviewed in [110,111].